1. HBW Insight
  2. >>Beauty
  3. >>Business
  4. >>Earnings

Kenvue Marks Independence By Extending Motrin And Tylenol Lines With Help From A Competitor

 
• By Malcolm Spicer

Kenvue also not standing apart from competitors concerning headwinds from foreign exchange rates, a slow start to the cough/cold season and looking ahead to FDA decision on oral phenylephrine, it reports with its third-quarter results.

• Source: Shutterstock

Kenvue Inc.’s early months as a standalone company, after Johnson & Johnson sold its controlling stake, haven’t meant it’s standing alone in the consumer health segment and isn’t working with competitors to expand its business.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

P&G: Innovation, Pricing ‘Short-Term Levers’ For Tariffs Adding Up To $1.5Bn In Costs Annually

 
• By Eileen Francis

The Procter & Gamble Company is working to mitigate the impact of tariffs, which will add up to $1.5bn in costs annually. The firm has lowered its fiscal 2025 outlook.

Beiersdorf Repositioning In China Will Get Boost From Thiamidol Launch

 
• By Eileen Francis

Beiersdorf AG hit some initial bumps with a repositioning of its business in China, but the firm is optimistic about the rollout of Thiamidol Skin Care In 2026.

L’Oréal, LVMH On First Quarter Challenges

 
• By Eileen Francis

L’Oréal Groupe reports in a first quarter presentation that its US business was more challenging than anticipated, while China “was slightly less bad” and Europe represented the best growth contributor. Separately, LVMH's Sephora sees ‘less momentum’ in its US business as competitor Amazon takes an aggressive position on beauty pricing.

Reducing Complexity Helps Weleda Break Sales Record

 
• By Tom Gallen

Swiss firm reports highest revenues in its history as restructure pays off for its pharma and cosmetics businesses in 2024.

More from Business